Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IMMX Stock Forecast 2025-2026
$1.87
Current Price
$51.01M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to IMMX Price Targets
+274.3%
To High Target of $7.00
+274.3%
To Median Target of $7.00
+274.3%
To Low Target of $7.00
IMMX Price Momentum
+12.7%
1 Week Change
+10.0%
1 Month Change
-12.2%
1 Year Change
-15.0%
Year-to-Date Change
-31.0%
From 52W High of $2.71
+48.4%
From 52W Low of $1.26
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Immix Biopharma (IMMX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on IMMX and similar high-potential opportunities.
Latest IMMX Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, IMMX has a bullish consensus with a median price target of $7.00 (ranging from $7.00 to $7.00). Currently trading at $1.87, the median forecast implies a 274.3% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Robert Burns at HC Wainwright & Co., projecting a 274.3% upside. Conversely, the most conservative target is provided by Robert Burns at HC Wainwright & Co., suggesting a 274.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IMMX Analyst Ratings
1
Buy
0
Hold
0
Sell
IMMX Price Target Range
Low
$7.00
Average
$7.00
High
$7.00
Current: $1.87
Latest IMMX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IMMX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 10, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Jan 6, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Oct 3, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Aug 19, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Jul 26, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Jul 9, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $7.00 |
| Jul 1, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Initiates | $7.00 |
| Aug 14, 2023 | Roth MKM | Jonathan Aschoff | Buy | Reiterates | $14.00 |
| Feb 22, 2023 | Roth MKM | Jonathan Aschoff | Buy | Initiates | $14.00 |
Immix Biopharma Inc. (IMMX) Competitors
The following stocks are similar to Immix Biopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Immix Biopharma Inc. (IMMX) Financial Data
Immix Biopharma Inc. has a market capitalization of $51.01M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -147.3%.
Valuation Metrics
Market Cap
$51.01M
Enterprise Value
$35.23M
P/E Ratio
0.0x
PEG Ratio
-3.3x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+34.1%
Current Ratio
2.3x
Debt/Equity
8.1x
ROE
-147.3%
ROA
-66.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Immix Biopharma Inc. (IMMX) Business Model
About Immix Biopharma Inc.
What They Do
Develops innovative therapies for oncology and immunotherapy.
Business Model
The company leverages its proprietary SMARxT Platform to enhance drug efficacy and safety, generating revenue through the development and commercialization of advanced cancer treatments. Immix Biopharma engages in various drug development stages, from pre-clinical to clinical trials, ensuring its therapies meet high standards of effectiveness.
Additional Information
Immix Biopharma is positioned as a significant player in the biotech sector, contributing to advancements in cancer treatment and attracting interest from researchers and investors. Its innovative approach aims to transform traditional cancer therapies, potentially improving patient outcomes significantly.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
18
CEO
Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Country
United States
IPO Year
2021
Website
www.immixbio.comImmix Biopharma Inc. (IMMX) Latest News & Analysis
Latest News
Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Data Selected for Oral Presentation at ASCO 2025
5 days ago
Quick Summary
Immix Biopharma's Phase 1/2 data on NXC-201 for relapsed/refractory AL Amyloidosis will be presented at ASCO 2025 in Chicago, May 30 - June 3, 2025, by Dr. Heather Landau.
Why It Matters
The presentation of positive Phase 1/2 trial data at ASCO 2025 can boost investor confidence in ImmixBio's potential, impacting stock performance and future funding opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Immix Biopharma's NXC-201 received FDA RMAT designation for relapsed/refractory AL amyloidosis, potentially expediting market approval. Next study update is set for H1 2025.
Why It Matters
FDA's RMAT designation for ImmixBio's NXC-201 enhances the likelihood of accelerated market approval, potentially boosting the company's stock and investor confidence in its prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Immix Biopharma (Nasdaq: IMMX) completed the Phase 1b safety run-in for its NEXICART-2 study on CAR-T therapy NXC-201 for relapsed/refractory AL Amyloidosis, with enrollment acceleration expected in January 2025.
Why It Matters
Successful Phase 1b results for Immix Biopharma's CAR-T therapy could boost investor confidence, potentially increasing stock value as enrollment accelerates for further trials.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Immix Biopharma's NXC-201 treatment showed positive results in four patients with AL Amyloidosis, normalizing disease markers within 30 days. Two achieved complete response. Update expected in H1 2025.
Why It Matters
Positive clinical results for NXC-201 could enhance ImmixBio's market position, increase investor confidence, and potentially drive stock prices up, especially ahead of further updates in 2025.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
4 months ago
Quick Summary
Immix Biopharma announced positive results for its CAR-T therapy NXC-201 in treating relapsed/refractory AL Amyloidosis, showing rapid complete responses in patients. Data published in JCO.
Why It Matters
The positive clinical results of NXC-201 for AL Amyloidosis may indicate strong market potential for Immix Biopharma, impacting stock performance and attracting investor interest in innovative therapies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
4 months ago
Quick Summary
Company management will update on positive developments regarding CAR-T NXC-201 for relapsed/refractory AL Amyloidosis, followed by a Q&A session.
Why It Matters
The update on CAR-T NXC-201's progress in treating AL Amyloidosis could indicate potential revenue growth and market expansion, influencing stock value and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About IMMX Stock
What is Immix Biopharma Inc.'s (IMMX) stock forecast for 2025?
Based on our analysis of 2 Wall Street analysts, Immix Biopharma Inc. (IMMX) has a median price target of $7.00. The highest price target is $7.00 and the lowest is $7.00.
Is IMMX stock a good investment in 2025?
According to current analyst ratings, IMMX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.87. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IMMX stock?
Wall Street analysts predict IMMX stock could reach $7.00 in the next 12 months. This represents a 274.3% increase from the current price of $1.87. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Immix Biopharma Inc.'s business model?
The company leverages its proprietary SMARxT Platform to enhance drug efficacy and safety, generating revenue through the development and commercialization of advanced cancer treatments. Immix Biopharma engages in various drug development stages, from pre-clinical to clinical trials, ensuring its therapies meet high standards of effectiveness.
What is the highest forecasted price for IMMX Immix Biopharma Inc.?
The highest price target for IMMX is $7.00 from Robert Burns at HC Wainwright & Co., which represents a 274.3% increase from the current price of $1.87.
What is the lowest forecasted price for IMMX Immix Biopharma Inc.?
The lowest price target for IMMX is $7.00 from Robert Burns at HC Wainwright & Co., which represents a 274.3% increase from the current price of $1.87.
What is the overall IMMX consensus from analysts for Immix Biopharma Inc.?
The overall analyst consensus for IMMX is bullish. Out of 2 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are IMMX stock price projections?
Stock price projections, including those for Immix Biopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 3:35 PM UTC